Apellis Pharmaceuticals I... (APLS)

Apellis Pharmaceuticals is a Buy due to the significant FCF potential of SYFOVRE® and EMPAVELI®, with SYFOVRE® projected to exceed $1bn in annual sales by 2028. SYFOVRE® has shown efficacy in slowing ...

APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.

A big quarterly earnings miss was the news driving down the value of Apellis Pharmaceuticals (APLS -5.99%) stock in the middle of the trading week. Investors didn't take this development well, and the...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Tracy Vineis – Vice President-Communications Cedric Francois – Co-Founder and ...

The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall...

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago.

Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.

The U.S. Food and Drug Administration (FDA) on Tuesday accepted and granted Priority Review designation to Apellis Pharmaceuticals, Inc.'s APLS supplemental New Drug Application (sNDA) for Empaveli (p...

Commerical stage Apellis Pharmaceuticals, Inc. recently reported Q4 results that beat expectations. The company posted impressive revenue growth and cost reduction in FY2024. It is a bit of a complica...